z-logo
open-access-imgOpen Access
Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation
Author(s) -
Qi Yang,
Jielin Tang,
Chonghui Xu,
He Zhao,
Yuan Zhou,
Yan-Yi Wang,
Min Yang,
Xinwen Chen,
Jizheng Chen
Publication year - 2020
Publication title -
journal of molecular cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.825
H-Index - 62
eISSN - 1674-2788
pISSN - 1759-4685
DOI - 10.1093/jmcb/mjaa043
Subject(s) - sumo protein , histone deacetylase , nf κb , histone , histone deacetylase 2 , chemistry , microbiology and biotechnology , cancer research , biology , signal transduction , biochemistry , dna , ubiquitin , gene
Protein modification by small ubiquitin-like modifier (SUMO) is an important regulatory mechanism for multiple cellular processes. Although the canonical pathway involving the ubiquitylation or phosphorylation of IκBα has been well characterized, little is known about the sumoylation of IκBα in the control of NF-κB activity. Here, we find that histone deacetylase 4 (HDAC4) negatively regulates tumor necrosis factor-alpha- or lipopolysaccharide-triggered NF-κB activation. HDAC4 belongs to the SUMO E3 ligase family and can directly sumoylate IκBα. The cytoplasm location of HDAC4 is essential for IκBα sumoylation. The Cys292 of HDAC4 is a key site for its SUMO E3 ligase activity. The sumoylation of IκBα prevents its polyubiquitination and degradation because these two modifications occur both at the Lys21. Our findings reveal a previously undiscovered role for HDAC4 in the inflammatory response as a SUMO E3 ligase for IκBα sumoylation. Our work provides insight into mechanisms ensuring optimal mediation of the NF-κB pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom